Project 1 will investigate the regulation of inflammation and lipid homeostasis in the context of macrophage foam cell formation and the pathogenesis of atherosclerosis. These studies will leverage our recent discovery that desmosterol, an intermediate in the cholesterol biosynthetic pathway, unexpectedly plays a key role in integration of the homeostatic response to excess cholesterol by activating LXR target genes required for cholesterol efflux, suppressing SREBP target genes involved in cholesterol and fatty acid biosynthesis, and inhibiting inflammatory responses by LXR-dependent and independent mechanisms. These findings have a number of unanticipated implications for understanding the pathophysiology of atherosclerosis and suggest new therapeutic approaches.
In Specific Aim 1, we will test the hypothesis that de-compensation of cholesterol homeostasis and 'expression of genes that amplify inflammatory responses in macrophage foam cells results from extrinsic, pro-inflammatory signals that are generated in the artery wall and induce TLR signaling.
In Specific Aim 2, we will test the hypothesis that in addition to serving as TLR-induced transcriptional activators of inflammatory-response genes, NFKB and IRF3 mediate TLR? dependent suppression of LXRs. Delineation of the mechanisms by which NFKB and IRF3 inhibit the lipid homeostatic and anti-inflammatory activities of LXRs may suggest new approaches for therapeutic intervention.
In Specific Aim 3, we will test the hypothesis that increasing endogenous levels of desmosterol or mimicking its activities will promote sterol excretion and inhibit the development of atherosclerosis. Conventional LXR ligands promote cholesterol efflux and inhibit atherosclerosis in mice, but are not useful drugs because they induce the expression of SREBP1c and cause marked hypertriglyceridemia. In contrast, desmosterol activates LXRs but suppresses SREBP processing. In this aim, we will investigate whether treatment with a putative desmosterol mimetic or raising endogenous desmosterol levels can be used as approaches to restore cholesterol homeostasis in lesion macrophages without causing adverse effects on circulating lipoprotein levels.

Public Health Relevance

Atherosclerosis remains a major cause of morbidity and mortality in industrialized societies. Although reduction of circulating cholesterol levels is an effective therapeutic strategy, not all patients at risk for disease respond to existing drugs. The proposed studies investigate new pathways and molecular mechanisms underlying the pathogenesis of atherosclerosis that could potentially be targeted for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL088093-06A1
Application #
8703250
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92093
van der Valk, Fleur M; Bekkering, Siroon; Kroon, Jeffrey et al. (2016) Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation 134:611-24
Zhao, Xuan; Hirota, Tsuyoshi; Han, Xuemei et al. (2016) Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation. Cell 165:1644-57
Wang, Junjian; Zou, June X; Xue, Xiaoqian et al. (2016) ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 22:488-96
Verbeek, Rutger; Boekholdt, S Matthijs; Stoekenbroek, Robert M et al. (2016) Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57:697-705
Yang, Xiaohong; Lee, Sang-Rok; Choi, Yun-Seok et al. (2016) Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res 57:706-13
Gordts, Philip L S M; Nock, Ryan; Son, Ni-Huiping et al. (2016) ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 126:2855-66
Wall, Christopher E; Yu, Ruth T; Atkins, Anne R et al. (2016) Nuclear receptors and AMPK: can exercise mimetics cure diabetes? J Mol Endocrinol 57:R49-58
Liu, Weilin; Struik, Dicky; Nies, Vera J M et al. (2016) Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 113:2288-93
Ley, Klaus (2016) 2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis. Arterioscler Thromb Vasc Biol 36:429-38
Miller, Yury I; Shyy, John Y-J (2016) Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation. Trends Endocrinol Metab :

Showing the most recent 10 out of 113 publications